European pharmaceutical group Recordati Tuesday announced the acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.
The products acquired are JHP-Rödler, BetadormD, Rhinopront, Collomack Topical, Tirgon and Xitix. The 2012 sales for the six products are estimated at around EUR 6 million.
Giovanni Recordati, chairman and CEO of the Recordati Group, said, "The OTC pharmaceutical segment in Germany represents 52 percent share in units of the overall pharmaceutical market."
Recordati added that together with the existing OTC portfolio, the German subsidiary will now be able to better exploit the OTC market potential by building a dedicated sales organization.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org